# DCTD - Predictive Drug Testing in Organoid Models

> **NIH NIH N01** · LEIDOS BIOMEDICAL RESEARCH, INC. · 2020 · $720,000

## Abstract

The Division of Cancer Treatment and Diagnosis, NCI is requesting the high-throughput screening (HTS) of approved and investigational agents in organoid models established from patient-derived tumor tissues. These studies will assist NCI in identifying drug responsive tumors and enable the active investigation of the underlying mechanism(s) of action, predictive biomarkers of response and/or resistance to agents, and the effects of genetic alterations on drug efficacy.  This project focuses on the use of organoid models to predict the efficacy of anti-cancer agents in various tumor types for further pre-clinical investigation by the NCI.

## Key facts

- **NIH application ID:** 10273265
- **Project number:** 75N91019D00024-0-759102000003-32
- **Recipient organization:** LEIDOS BIOMEDICAL RESEARCH, INC.
- **Principal Investigator:** LEONARD FREEDMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $720,000
- **Award type:** —
- **Project period:** 2020-08-31 → 2021-08-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10273265

## Citation

> US National Institutes of Health, RePORTER application 10273265, DCTD - Predictive Drug Testing in Organoid Models (75N91019D00024-0-759102000003-32). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10273265. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*